Charles Schwab’s Adverum Biotechnologies ADVM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-49,024
| Closed | -$214K | – | 3497 |
|
|
2025
Q1 | $214K | Sell |
49,024
-10,710
| -18% | -$48.3K | ﹤0.01% | 3249 |
|
|
2024
Q4 | $279K | Hold |
59,734
| – | – | ﹤0.01% | 3282 |
|
|
2024
Q3 | $419K | Hold |
59,734
| – | – | ﹤0.01% | 3205 |
|
|
2024
Q2 | $410K | Buy |
59,734
+49,021
| +458% | +$456K | ﹤0.01% | 3278 |
|
|
2024
Q1 | $151K | Buy |
10,713
+7,072
| +194% | +$108K | ﹤0.01% | 3267 |
|
|
2023
Q4 | $27.4K | Hold |
3,641
| – | – | ﹤0.01% | 3458 |
|
|
2023
Q3 | $54.6K | Hold |
3,641
| – | – | ﹤0.01% | 3400 |
|
|
2023
Q2 | $57.9K | Sell |
3,641
-2,650
| -42% | -$27.9K | ﹤0.01% | 3402 |
|
|
2023
Q1 | $45.1K | Hold |
6,291
| – | – | ﹤0.01% | 3364 |
|
|
2022
Q4 | $36.5K | Hold |
6,291
| – | – | ﹤0.01% | 3423 |
|
|
2022
Q3 | $60K | Buy |
+6,291
| New | +$82.7K | ﹤0.01% | 3292 |
|
|
2022
Q2 | – | Sell |
-19,589
| Closed | -$257K | – | 3540 |
|
|
2022
Q1 | $257K | Sell |
19,589
-2,025
| -9% | -$29.6K | ﹤0.01% | 3259 |
|
|
2021
Q4 | $381K | Hold |
21,614
| – | – | ﹤0.01% | 3233 |
|
|
2021
Q3 | $470K | Sell |
21,614
-40,077
| -65% | -$1.02M | ﹤0.01% | 3166 |
|
|
2021
Q2 | $2.16M | Buy |
61,691
+580
| +0.9% | +$31.2K | ﹤0.01% | 2691 |
|
|
2021
Q1 | $6.03M | Buy |
61,111
+1,781
| +3% | +$214K | ﹤0.01% | 2202 |
|
|
2020
Q4 | $6.43M | Buy |
59,330
+2,062
| +4% | +$255K | ﹤0.01% | 2092 |
|
|
2020
Q3 | $5.9M | Buy |
57,268
+12,028
| +27% | +$1.8M | ﹤0.01% | 1986 |
|
|
2020
Q2 | $9.45M | Buy |
45,240
+6,724
| +17% | +$1.19M | ﹤0.01% | 1685 |
|
|
2020
Q1 | $3.76M | Buy |
38,516
+5,578
| +17% | +$650K | ﹤0.01% | 1971 |
|
|
2019
Q4 | $3.79M | Buy |
32,938
+778
| +2% | +$68.6K | ﹤0.01% | 2170 |
|
|
2019
Q3 | $1.75M | Buy |
32,160
+19,166
| +147% | +$2.16M | ﹤0.01% | 2425 |
|
|
2019
Q2 | $1.55M | Buy |
12,994
+381
| +3% | +$31.5K | ﹤0.01% | 2444 |
|
|
2019
Q1 | $661K | Buy |
12,613
+1,245
| +11% | +$50.3K | ﹤0.01% | 2666 |
|
|
2018
Q4 | $359K | Hold |
11,368
| – | – | ﹤0.01% | 2878 |
|
|
2018
Q3 | $688K | Hold |
11,368
| – | – | ﹤0.01% | 2734 |
|
|
2018
Q2 | $603K | Buy |
+11,368
| New | +$684K | ﹤0.01% | 2746 |
|
|
2017
Q2 | – | Sell |
-2,821
| Closed | -$77K | – | 3102 |
|
|
2017
Q1 | $77K | Hold |
2,821
| – | – | ﹤0.01% | 3028 |
|
|
2016
Q4 | $82K | Hold |
2,821
| – | – | ﹤0.01% | 3054 |
|
|
2016
Q3 | $116K | Hold |
2,821
| – | – | ﹤0.01% | 3002 |
|
|
2016
Q2 | $90K | Hold |
2,821
| – | – | ﹤0.01% | 3063 |
|
|
2016
Q1 | $146K | Hold |
2,821
| – | – | ﹤0.01% | 2948 |
|
|
2015
Q4 | $269K | Hold |
2,821
| – | – | ﹤0.01% | 2897 |
|
|
2015
Q3 | $233K | Hold |
2,821
| – | – | ﹤0.01% | 2918 |
|
|
2015
Q2 | $459K | Buy |
2,821
+1,811
| +179% | +$611K | ﹤0.01% | 2702 |
|
|
2015
Q1 | $410K | Hold |
1,010
| – | – | ﹤0.01% | 2703 |
|
|
2014
Q4 | $546K | Buy |
+1,010
| New | +$389K | ﹤0.01% | 2587 |
|
Other funds holding ADVM
BCM
PWA
TCM
FLSM
5VM
VVM
Charles Schwab's ADVM Position: Q2 2025 in Review
Charles Schwab sold out of Adverum Biotechnologies (ADVM) in Q2 2025, closing a stake of 49,024 shares — an estimated $214K sold.
Charles Schwab first reported a position in ADVM in Q4 2014 and held it in 37 quarters. The position peaked at $9.45M in Q2 2020. 58 funds tracked by Wall St. Rank hold ADVM as of Q2 2025.
- Charles Schwab reported no remaining Adverum Biotechnologies position as of Q2 2025 after selling out during the quarter.
- Charles Schwab sold 49,024 Adverum Biotechnologies shares in Q2 2025, an estimated $214K.
- Charles Schwab first reported a position in Adverum Biotechnologies in Q4 2014 and held it in 37 quarters.
- Charles Schwab's Adverum Biotechnologies position peaked at $9.45M in Q2 2020.
- 58 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2025.
Based on Charles Schwab's 13F filing for Q2 2025, filed 12 Aug 2025.